Valeant Pharmaceuticals Intl Inc (VRX) : Pomelo Capital scooped up 294,900 additional shares in Valeant Pharmaceuticals Intl Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 724,900 shares of Valeant Pharmaceuticals Intl Inc which is valued at $18,064,508.Valeant Pharmaceuticals Intl Inc makes up approximately 20.57% of Pomelo Capital’s portfolio.
Other Hedge Funds, Including , Weik Investment Services Inc reduced its stake in VRX by selling 470 shares or 1.2% in the most recent quarter. The Hedge Fund company now holds 38,630 shares of VRX which is valued at $962,660. Valeant Pharmaceuticals Intl Inc makes up approx 0.55% of Weik Investment Services Inc’s portfolio.Advisors Asset Management reduced its stake in VRX by selling 2,650 shares or 12.49% in the most recent quarter. The Hedge Fund company now holds 18,567 shares of VRX which is valued at $454,706. Valeant Pharmaceuticals Intl Inc makes up approx 0.01% of Advisors Asset Management’s portfolio. Neuberger Berman Group sold out all of its stake in VRX during the most recent quarter. The investment firm sold 8,063 shares of VRX which is valued $177,063.Glenmede Trust Co Na boosted its stake in VRX in the latest quarter, The investment management firm added 1,593 additional shares and now holds a total of 3,585 shares of Valeant Pharmaceuticals Intl Inc which is valued at $78,727.Equitec Proprietary Markets reduced its stake in VRX by selling 27,300 shares or 89.22% in the most recent quarter. The Hedge Fund company now holds 3,300 shares of VRX which is valued at $75,306. Valeant Pharmaceuticals Intl Inc makes up approx 0.16% of Equitec Proprietary Markets’s portfolio.
Valeant Pharmaceuticals Intl Inc closed down -0.07 points or -0.22% at $31.2 with 2,98,03,705 shares getting traded on Tuesday. Post opening the session at $31.83, the shares hit an intraday low of $30.9505 and an intraday high of $31.99 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $1.48. The company had revenue of $2420.20 million for the quarter, compared to analysts expectations of $2451.77 million. The company’s revenue was down -11.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.14 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Company shares were Upgraded by Morgan Stanley on Aug 17, 2016 to ” Overweight”, Firm has raised the Price Target to $ 42 from a previous price target of $33 .Company shares were Upgraded by Mizuho on Aug 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $11 .Company shares were Reiterated by Piper Jaffray on Aug 10, 2016 to “Underweight”, Firm has raised the Price Target to $ 22 from a previous price target of $19 .
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.